

1 **Associations between vitamin D and disease risk may be attributed to**
2 **the confounding influence of adiposity during childhood and adulthood:**
3 **a lifecourse Mendelian randomization study**

4

5 Tom G Richardson^{1,2*}, Grace M Power¹, George Davey Smith¹

6

7 ¹ *MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of*
8 *Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom*

9 ² *Novo Nordisk Research Centre, Headington, Oxford, OX3 7FZ, United Kingdom*

10

11 **Running title:** Time-varying effects of adiposity on vitamin D levels

12

13 **Keywords:** Mendelian randomization, Lifecourse epidemiology, Childhood adiposity,
14 Vitamin D, ALSPAC

15

16 **Word count:** 1,078

17

18 **Total number of figures and tables:** 1

19

20 **Abstract**

21 **Background:** Vitamin D supplements are widely prescribed to help reduce disease risk.
22 However, this strategy is based on findings using conventional epidemiological methods
23 which are prone to confounding and reverse causation.

24 **Methods:** In this short report, we leveraged genetic variants which differentially influence
25 body size during childhood and adulthood within a multivariable Mendelian randomization
26 (MR) framework, allowing us to separate the genetically predicted effects of adiposity at
27 these two timepoints in the lifecourse.

28 **Results:** Using data from the Avon Longitudinal Study of Parents and Children (ALSPAC),
29 there was strong evidence that higher childhood body size has a direct effect on lower
30 vitamin D levels in early life (mean age: 9.9 years, range=8.9 to 11.5 years) after accounting
31 for the effect of the adult body size genetic score (Beta=-0.32, 95% CI=-0.54 to -0.10,
32 P=0.004). Conversely, we found evidence that the effect of childhood body size on vitamin
33 D levels in midlife (mean age: 56.5 years, range=40 to 69 years) is putatively mediated
34 along the causal pathway involving adulthood adiposity (Beta=-0.17, 95% CI=-0.21 to -0.13,
35 P=4.6x10⁻¹⁷).

36 **Conclusions:** Our findings have important clinical implications in terms of the causal
37 influence of vitamin D deficiency on disease risk. Furthermore, they serve as a compelling
38 proof of concept that the timepoints across the lifecourse at which exposures and outcomes
39 are measured can meaningfully impact overall conclusions drawn by MR studies.

40 **Funding:** This work was supported by the Integrative Epidemiology Unit which receives
41 funding from the UK Medical Research Council and the University of Bristol
42 (MC_UU_00011/1).

43

44 Introduction

45 Associations between vitamin D deficiency and disease risk have been widely reported by
46 conventional epidemiological studies, including diseases which typically have a late-onset
47 over the lifecourse, such as coronary artery disease, but also those which may be diagnosed
48 in early life such as type 1 diabetes (T1D). As a result, vitamin D supplements are widely
49 prescribed with an estimated 18% of adults in the USA reportedly taking supplements daily
50 (Rooney *et al.*, 2017). However, there is increasing evidence from the literature suggesting
51 that vitamin D supplements may be ineffective at reducing disease risk in the population
52 (Murai *et al.*, 2021), and although there are notable exceptions (e.g. multiple sclerosis
53 (Mokry *et al.*, 2015, Vandeborgh *et al.*, 2022)), this raises uncertainty into the causal effects
54 of vitamin D levels on many disease outcomes. Furthermore, these conventional
55 associational studies may have been susceptible to bias, given that vitamin D levels are
56 known to differ amongst individuals based on various lifestyle factors, including their body
57 mass index (BMI), as well as being prone to reverse causation, for example due to
58 inflammatory processes which are known to lower vitamin D levels (Preiss and Sattar,
59 2019).

60
61 An approach to mitigate the influence of these sources of bias is Mendelian randomization
62 (MR), a causal inference technique which exploits the random allocation of genetic variants
63 at birth to evaluate the genetically predicted effects of modifiable exposures on disease
64 outcomes and circulating biomarkers (Davey Smith and Ebrahim, 2003, Richmond and
65 Davey Smith, 2022). For example, MR has been applied in recent years to suggest that
66 vitamin D supplements are unlikely to have a beneficial effect on risk of type 1 diabetes
67 (Manousaki *et al.*, 2021). We previously extended the application of MR to investigate
68 epidemiological hypotheses in lifecourse setting (known to as 'lifecourse MR'), by deriving
69 sets of genetic variants to separate the independent effects of body size during childhood
70 and adulthood within a multivariable framework (Richardson *et al.*, 2020). Applying this
71 approach has highlighted the putative causal role that early life adiposity may have on
72 outcomes such as T1D risk (Richardson *et al.*, 2022) and cardiac structure (O'Nunain *et al.*
73 (in press)). In contrast, we have demonstrated that it's influence on other disease outcomes

74 (e.g. cardiovascular disease (Power *et al.*, 2021)) is likely attributed to the long-term
75 consequence of remaining overweight into later life. Whilst these applications serve as
76 powerful examples of lifecourse MR as an approach to separate the effects of the same
77 exposure based on data derived from early and later life, it has yet to be applied to the
78 same outcome when measured at different timepoints in the lifecourse.

79


80 **Results**

81 In this study, we applied lifecourse MR to investigate the independent effects of childhood
82 and adult body size has a largely indirect influence on 25-hydroxyvitamin D (25OHD) levels
83 measured during childhood (mean age: 9.9 years, range=8.9 to 11.5 years) using
84 individual-level data from the Avon Longitudinal Study of Parents and Children (ALSPAC)
85 (Boyd *et al.*, 2013, Fraser *et al.*, 2013) and during adulthood (mean age: 56.5 years,
86 range=40 to 69 years) using summary-level data based on individuals from the UK Biobank
87 (UKB) study (Manousaki *et al.*, 2020). Firstly, using data derived from the ALSPAC study,
88 our analyses indicated that childhood body size directly influences vitamin D levels during
89 childhood after accounting for the adult body size genetic instrument in our model (Beta=-
90 0.32 standard deviation (SD) change in natural log-transformed 25OHD per change in body
91 size category, 95% CI=-0.54 to -0.10, P=0.004) (**Figure 1A & Figure 1B**). Using data from
92 the UKB study, evidence of an effect of higher childhood body size on adulthood measured
93 25OHD levels (Beta=-0.14, 95% CI=-0.10 to -0.03, P=2.4x10⁻⁴) attenuated in a multivariate
94 setting upon accounting for adulthood body size (Beta=0.04, 95% CI=-0.01 to 0.08, P=0.10).
95 In contrast, strong evidence of an effect for higher adult body size on lower 25OHD levels
96 measured in adulthood was found in the multivariable model (Beta=-0.17, 95% CI=-0.21 to
97 -0.13, P=4.6x10⁻¹⁷) (**Figure 1C**). This suggests that childhood body size has an indirect
98 influence of 25OHD levels in adulthood, likely due to its persistent effect throughout the
99 lifecourse (**Figure 1D**).

100

101 **Figure 1**

102



103

104 *A) A forest plot illustrating the direct effect of childhood body size on circulating vitamin D levels measured during childhood*
 105 *(mean age: 9.9 years) using participant data from the Avon Longitudinal Study of Parents and Children (ALSPAC) with the*
 106 *corresponding schematic diagram for this finding being located in panel B). C) A forest plot depicting the indirect effect of*
 107 *childhood body size on adulthood measured vitamin D levels using data from the UK Biobank study (mean age: X years) as*
 108 *described in the schematic diagram presented in panel D). MR – Mendelian randomization.*

109

110 Discussion

111 Our findings suggest that increased adiposity exerts a strong effect on lower vitamin D
112 levels during both childhood and adulthood. Separating causal from confounding factors,
113 particularly in a lifecourse setting, would have been extremely challenging to disentangle
114 without the use of genetic variants as achieved in this study. In contrast, appropriately
115 accounting for confounding factors in an conventional epidemiological setting is
116 notoriously challenging, with previous studies reporting evidence of association between
117 vitamin D and T1D in early life even after adjusting for factors such as birthweight
118 (Hypponen *et al.*, 2001). Taken together with evidence from previous MR studies, which
119 have found that childhood body size (Richardson *et al.*, 2022), but not vitamin D levels
120 (Manousaki *et al.*, 2021), increases risk of T1D, our results suggest that adiposity may have
121 acted as a confounding factor on the observed association between vitamin D and T1D.
122 These findings therefore have important clinical implications in terms of whether patients
123 newly diagnosed with T1D should be prescribed vitamin D supplements or not.

124

125 Effect estimates derived from MR studies are conventionally interpreted as 'lifelong effects'
126 given that the germline genetic variants harnessed by this approach as instrumental
127 variables are typically fixed at conception. The results of this study serve as a compelling
128 demonstration that the timepoint at which both exposures and outcomes are measured
129 across the lifecourse can meaningfully impact conclusions drawn by MR investigations.
130 Whilst the childhood and adult body size genetic scores were used in this study as a proof
131 of concept, our findings also help to further validate their utility in separating the temporal
132 effects of adiposity within a lifecourse MR framework. Overall, these findings emphasise
133 the importance of future MR studies taking further consideration into the age of
134 participants that their genetic estimates are based on, as well as the age at which cases are
135 diagnosed for disease outcome estimates, before interpreting and drawing conclusions
136 from their findings. Furthermore, our results highlight the importance of conducting
137 genome-wide association studies on populations of different age groups to help uncover
138 time-varying genetic effects scattered throughout the human genome. Findings from these
139 endeavours should facilitate insight into the direct and indirect effects of modifiable early

140 life exposures using approaches such as lifecourse MR. This may help to elucidate the
141 critical timepoints whereby conferred risk by these exposures on disease outcomes starts
142 to become immutable, which has important implications for improving patient care in a
143 clinical setting.

144 **Materials and Methods**

145 ALSPAC is a population-based cohort investigating genetic and environmental factors that
146 affect the health and development of children. The study methods are described in detail
147 elsewhere (Boyd *et al.*, 2013, Fraser *et al.*, 2013). In brief, 14,541 pregnant women
148 residents in the former region of Avon, UK, with an expected delivery date between April 1,
149 1991 and December 31, 1992, were eligible to take part in ALSPAC. Detailed phenotypic
150 information, biological samples and genetic data which have been collected from the
151 ALSPAC participants are available through a searchable data dictionary ([http://
152 www.bris.ac.uk/alspac/researchers/our-data/](http://www.bris.ac.uk/alspac/researchers/our-data/)). Written informed consent was obtained
153 for all study participants. Ethical approval for this study was obtained from the ALSPAC
154 Ethics and Law Committee and the Local Research Ethics Committees. Measures of 25-
155 hydroxyvitamin D (25OHD) levels were obtained from non-fasting blood samples taken
156 from ALSPAC participants at mean age 9.9 years (range=8.9 to 11.5 years) which were log
157 transformed to ensure normality.

158
159 Derivation of genetic instruments for childhood and adulthood body size have been
160 described in detail previously (Richardson *et al.*, 2020). In brief, genome-wide association
161 studies (GWAS) were conducted on 463,005 UK Biobank (UKB) participants (mean age:
162 56.5 years, range=40 to 69 years) who had both reported their body size at age 10 as well
163 as had their BMI clinically measured. Genetic instruments were identified from these
164 analyses (based on $P < 5 \times 10^{-8}$) and the resulting genetic score for childhood body size has
165 been validated using measured childhood BMI in ALSPAC (Richardson *et al.*, 2020), the
166 Young Finns Study (Richardson *et al.*, 2021) and the Trøndelag Health (HUNT) study
167 (Brandkvist *et al.*, 2020). Genetic estimates on adulthood 25OHD were obtained from a
168 previously conducted GWAS in UKB (Manousaki *et al.*, 2020). Despite having overlapping
169 samples when analysing our body size instruments against the adulthood measure of

170 vitamin D, there was little evidence of inflated type 1 error rates (based on the calculator at
171 <https://sb452.shinyapps.io/overlap>) (Burgess *et al.*, 2016).

172
173 Mendelian randomization (MR) analyses to estimate genetically predicted effects on
174 childhood 25OHD were conducted in a one-sample setting using individual level data from
175 ALSPAC after generating genetic risk scores for our body size instruments with adjustment
176 for age and sex. MR analyses to estimate effects on adulthood 25OHD were undertaken in a
177 two-sample setting using the inverse variance weighted (IVW) method (Burgess *et al.*,
178 2013), as this allowed us to additionally perform analyses using the weighted median and
179 MR-Egger methods (Bowden *et al.*, 2015, Bowden *et al.*, 2016). (**Supplementary Table 1**).
180 Multivariable MR were performed in one- and two-sample settings respectively for
181 childhood and adulthood measures of 25OHD (Sanderson *et al.*, 2019) (**Supplementary**
182 **Table 2**).

183

184 **Data availability**

185 All individual level data analysed in this study can be accessed via an approved application
186 to ALSPAC (<http://www.bristol.ac.uk/alspac/researchers/access/>). Summary-level data on
187 adulthood vitamin D levels can be accessed publicly via the OpenGWAS
188 (<https://gwas.mrcieu.ac.uk/>).

189 **Consent**

190 Written informed consent was obtained for all study participants. Ethical approval for this
191 study was obtained from the ALSPAC Ethics and Law Committee and the Local Research
192 Ethics Committees.

193 **Competing Interests**

194 TGR is employed part-time by Novo Nordisk outside of this work. All other authors declare
195 no conflicts of interest.

196 **Funding**

197 This work was supported by the Integrative Epidemiology Unit which receives funding
198 from the UK Medical Research Council and the University of Bristol (MC_UU_00011/1).

199 **Acknowledgements**

200 We are extremely grateful to all the families who took part in this study, the midwives for
201 their help in recruiting them and the whole ALSPAC team, which includes interviewers,
202 computer and laboratory technicians, clerical workers, research scientists, volunteers,
203 managers, receptionists and nurses. The UK Medical Research Council and Wellcome
204 (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC.
205 Consent for biological samples has been collected in accordance with the Human Tissue Act
206 (2004). GWAS data was generated by Sample Logistics and Genotyping Facilities at
207 Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using
208 support from 23andMe.

209

210 This research was conducted at the NIHR Biomedical Research Centre at the University
211 Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed
212 in this publication are those of the author(s) and not necessarily those of the NHS, the
213 National Institute for Health Research or the Department of Health. This publication is the
214 work of the authors and TGR will serve as guarantor for the contents of this paper.

215 **References**

- 216 Bowden, J., Davey Smith, G. & Burgess, S. 2015. Mendelian randomization with invalid
217 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*, 44,
218 512-25.
- 219 Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. 2016. Consistent Estimation in
220 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator.
221 *Genet Epidemiol*, 40, 304-14.
- 222 Boyd, A., Golding, J., Macleod, J., Lawlor, D. A., Fraser, A., Henderson, J., Molloy, L., Ness,
223 A., Ring, S. & Davey Smith, G. 2013. Cohort Profile: the 'children of the 90s'--the index
224 offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol*, 42, 111-27.
- 225 Brandkvist, M., Bjorngaard, J. H., Odegard, R. A., Asvold, B. O., Smith, G. D., Brumpton, B.,
226 Hveem, K., Richardson, T. G. & Vie, G. A. 2020. Separating the genetics of childhood and adult
227 obesity: a validation study of genetic scores for body mass index in adolescence and adulthood in
228 the HUNT Study. *Hum Mol Genet*.
- 229 Burgess, S., Butterworth, A. & Thompson, S. G. 2013. Mendelian randomization analysis with
230 multiple genetic variants using summarized data. *Genet Epidemiol*, 37, 658-65.
- 231 Burgess, S., Davies, N. M. & Thompson, S. G. 2016. Bias due to participant overlap in two-
232 sample Mendelian randomization. *Genet Epidemiol*, 40, 597-608.
- 233 Davey Smith, G. & Ebrahim, S. 2003. 'Mendelian randomization': can genetic epidemiology
234 contribute to understanding environmental determinants of disease? *Int J Epidemiol*, 32, 1-22.
- 235 Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G.,
236 Henderson, J., Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S. M. & Lawlor, D. A. 2013.
237 Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort.
238 *Int J Epidemiol*, 42, 97-110.
- 239 Hypponen, E., Laara, E., Reunanen, A., Jarvelin, M. R. & Virtanen, S. M. 2001. Intake of
240 vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet*, 358, 1500-3.
- 241 Manousaki, D., Harroud, A., Mitchell, R. E., Ross, S., Forgetta, V., Timpson, N. J., Smith, G. D.,
242 Polychronakos, C. & Richards, J. B. 2021. Vitamin D levels and risk of type 1 diabetes: A
243 Mendelian randomization study. *PLoS Med*, 18, e1003536.
- 244 Manousaki, D., Mitchell, R., Dudding, T., Haworth, S., Harroud, A., Forgetta, V., Shah, R. L.,
245 Luan, J., Langenberg, C., Timpson, N. J. & Richards, J. B. 2020. Genome-wide Association
246 Study for Vitamin D Levels Reveals 69 Independent Loci. *Am J Hum Genet*, 106, 327-337.
- 247 Mokry, L. E., Ross, S., Ahmad, O. S., Forgetta, V., Smith, G. D., Goltzman, D., Leong, A.,
248 Greenwood, C. M., Thanassoulis, G. & Richards, J. B. 2015. Vitamin D and Risk of Multiple
249 Sclerosis: A Mendelian Randomization Study. *PLoS Med*, 12, e1001866.
- 250 Murai, I. H., Fernandes, A. L., Sales, L. P., Pinto, A. J., Goessler, K. F., Duran, C. S. C., Silva,
251 C. B. R., Franco, A. S., Macedo, M. B., Dalmolin, H. H. H., Baggio, J., Balbi, G. G. M., Reis, B.

252 Z., Antonangelo, L., Caparbo, V. F., Gualano, B. & Pereira, R. M. R. 2021. Effect of a Single
253 High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe
254 COVID-19: A Randomized Clinical Trial. *JAMA*, 325, 1053-1060.

255 Power, G. M., Tyrrell, J., Frayling, T. M., Davey Smith, G. & Richardson, T. G. 2021.
256 Mendelian Randomization Analyses Suggest Childhood Body Size Indirectly Influences End
257 Points From Across the Cardiovascular Disease Spectrum Through Adult Body Size. *J Am Heart*
258 *Assoc*, 10, e021503.

259 Preiss, D. & Sattar, N. 2019. Research digest: vitamin D supplementation. *Lancet Diabetes*
260 *Endocrinol*, 7, 91.

261 Richardson, T. G., Crouch, D. J. M., Power, G. M., Berstein, F. M., Hazelwood, E., Fang, S.,
262 Cho, Y., Inshaw, J. R. J., Robertson, C. C., Sidore, C., Cucca, F., Rich, S. S., Todd, J. A. &
263 Smith, G. D. 2022. Childhood body size directly increases type 1 diabetes risk based on a
264 lifecourse Mendelian randomization approach. *Nat Commun (in press)*.

265 Richardson, T. G., Mykkanen, J., Pahkala, K., Ala-Korpela, M., Bell, J. A., Taylor, K., Viikari,
266 J., Lehtimäki, T., Raitakari, O. & Davey Smith, G. 2021. Evaluating the direct effects of
267 childhood adiposity on adult systemic metabolism: a multivariable Mendelian randomization
268 analysis. *Int J Epidemiol*.

269 Richardson, T. G., Sanderson, E., Elsworth, B., Tilling, K. & Davey Smith, G. 2020. Use of
270 genetic variation to separate the effects of early and later life adiposity on disease risk:
271 mendelian randomisation study. *BMJ*, 369, m1203.

272 Richmond, R. C. & Davey Smith, G. 2022. Mendelian Randomization: Concepts and Scope.
273 *Cold Spring Harb Perspect Med*, 12.

274 Rooney, M. R., Harnack, L., Michos, E. D., Ogilvie, R. P., Sempos, C. T. & Lutsey, P. L. 2017.
275 Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International
276 Units Daily, 1999-2014. *JAMA*, 317, 2448-2450.

277 Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. 2019. An examination of
278 multivariable Mendelian randomization in the single-sample and two-sample summary data
279 settings. *Int J Epidemiol*, 48, 713-727.

280 Vandebergh, M., Degryse, N., Dubois, B. & Goris, A. 2022. Environmental risk factors in
281 multiple sclerosis: bridging Mendelian randomization and observational studies. *J Neurol*.
282
283